The global high content screening market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of 8.2% during 2021-2026, according to the latest report by IMARC Group.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
High-content screening (HCS), or cellomics, refers to the analytical method that combines automated imaging and quantitative data analysis to evaluate various biochemical and physical characteristics of sample cells. It aids in drug discovery, complex multivariate drug profiling and toxicity studies by utilizing robots, detectors and software to monitor the entire process.